Replimune Group (NasdaqGS:REPL) 2026 Conference Transcript

Summary of Replimune Group Conference Call Company Overview - Company: Replimune Group (NasdaqGS:REPL) - Focus: Development of next-generation oncolytic immunotherapy based on HSV platform - Lead Assets: - RP1: Targeting advanced melanoma, with a PDUFA date set for April 10, 2026 - RP2: Targeting uveal melanoma, with ongoing registrational trial REVEAL Regulatory Updates - RP1: - Received Breakthrough Therapy designation from the FDA in mid-2024 - Initial BLA application resulted in a complete response letter (CRL) in July 2024 - Resubmission of BLA accepted, with ongoing information requests from the FDA - Confidence in approval due to high unmet need in anti-PD-1 failed melanoma space and strong physician support [7][8][10] Clinical Data and Efficacy - RP1 Efficacy: - 33% response rate in combination with nivolumab for patients with confirmed PD-1 failure, compared to a 5%-7% expected response rate from further PD-1 treatments [13][14] - Durable responses exceeding 2 years anticipated for patients [21] Commercial Readiness - Sales and Marketing: - Maintained sales organization focused on deep profiling of customers and preparing for launch - Targeting 150 accounts primarily in academic and hospital settings for initial launch [19][20][25] - Commercial stock being built up in anticipation of launch, with physicians expressing readiness for RP1 [20] Market Opportunity - Addressable Market: - Estimated 10,000 addressable patients in the U.S. for RP1 in post-PD-1 cutaneous melanoma setting [24] - Focus on both academic centers and community practices for broader adoption over time [25][26] Future Development Plans - RP2: - Designed for more immunologically inactive tumors, currently enrolling patients in the REVEAL trial for uveal melanoma [36][37] - Plans to explore additional indications, including primary liver cancer (HCC) and biliary tract cancer (BTC) [40][41] Financial Position - Cash Position: - Ended the year with approximately $269 million, with an additional $35 million in debt taken on, providing runway into early 2027 [44] Upcoming Milestones - Key Catalysts: - Awaiting PDUFA date for RP1 approval - Data expected from HCC/BTC studies and REVEAL trial in early next year, with potential for earlier data release [45][46] Additional Insights - Physician Engagement: - Positive feedback from clinicians and increased hands-on experience with RP1 through compassionate use and clinical trials [22][23] - Potential Impact of Approval Delay: - In case of further delays, cost-cutting measures may be necessary, but preserving value in ongoing programs will be prioritized [43]